The failure of anti-EGFR treatments in these patients is also confirmed by the major effectiveness of intensified treatments such as “FOLFOXIRI regimen” to restrain the tumor progression, although the predictive role of BRAFmut has not been defined in the response to cetuximab or panitumumab (23). Here, EGFR is linked to neoplasm.